Pharmacotherapy II: narcotic and narcotic-antagonists analgesics.
D000588:Amines / Q000502:physiology; D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use*; D000701:Analgesics, Opioid / Q000494:pharmacology / Q000627:therapeutic use*; D001665:Binding Sites; D001921:Brain / Q000187:drug effects; D001923:Brain Chemistry; D003061:Codeine / Q000627:therapeutic use; D004361:Drug Tolerance; D004745:Enkephalins / Q000302:isolation & purification; D006801:Humans; D008614:Meperidine / Q000627:therapeutic use; D009020:Morphine / Q000494:pharmacology; D009270:Naloxone / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D009892:Opium / Q000494:pharmacology; D010146:Pain / Q000188:drug therapy* / Q000503:physiopathology; D010423:Pentazocine / Q000627:therapeutic use; D011957:Receptors, Opioid / Q000502:physiology; D012964:Sodium / Q000494:pharmacology; D019966:Substance-Related Disorders
D000588:Amines; D000700:Analgesics; D000701:Analgesics, Opioid; D004745:Enkephalins; D009292:Narcotic Antagonists; D011957:Receptors, Opioid; D009270:Naloxone; D009020:Morphine; D009892:Opium; D008614:Meperidine; D012964:Sodium; D010423:Pentazocine; D003061:Codeine